Odd-chain fatty acids occupy an unusual corner of nutritional biochemistry. Unlike the even-chain fats that dominate most dietary fat discussions, C15 (pentadecanoic acid) and C17:0 (heptadecanoic acid, also called margaric acid) contain an odd number of carbon atoms and follow subtly different metabolic routes. Both accumulate primarily through the consumption of full-fat dairy and ruminant fat, and both have attracted scientific attention as potential biomarkers for those dietary patterns.
Over the past decade, researchers have moved beyond treating these two fatty acids as interchangeable. Evidence now suggests they differ in their circulating behavior, their degree of endogenous synthesis, and their associations with metabolic outcomes. This article compares C15 and C17:0 across those dimensions, drawing on peer-reviewed evidence while being clear about where the science remains preliminary or observational.
Key Takeaways
- C15 (pentadecanoic acid) and C17:0 (margaric acid) are both naturally occurring odd-chain fatty acids found primarily in full-fat dairy and ruminant fat, but C15 is the better-supported dairy-fat marker: C17:0 did not differ between dairy, meat and grain diets in one crossover trial, and higher milk fat intake went with lower serum 17:0 in another [11][12].
- C17:0 has greater potential for endogenous synthesis compared to C15, which can complicate its use as a purely dietary biomarker and gives the two acids distinct metabolic backgrounds [1].
- Both fatty acids show mostly favorable signals in observational cardiometabolic research, with exceptions, including [13][8] an inverse association with hypertension in NHANES data [2], but these are associations, not proven causal relationships.
- In rats, circulating C15 fell as total dietary fat rose (a roughly 30% rise in dietary fat gave a roughly 35% drop in C15) while C17:0 did not change significantly, so blood C15 does not simply track intake[3].
- Dedicated supplementation research exists only for C15; C17:0 is characterized primarily through epidemiological observation, and neither fatty acid has been evaluated by the FDA for any disease indication.
What Are Odd-Chain Fatty Acids and Where Do They Come From?
Fatty acids are classified partly by chain length and partly by whether that length is even or odd. Even-chain fatty acids, the most familiar dietary fats, are assembled two carbons at a time from acetyl-CoA. Odd-chain fatty acids terminate on a 15- or 17-carbon backbone, producing a fundamentally different terminal unit (propionyl-CoA) when fully oxidized. This biochemical difference affects how these fats are metabolized and which tissues they interact with [1].
For humans, dietary C15 and C17:0 come predominantly from full-fat dairy products (butter, cheese, whole milk) and meat from ruminant animals. Ruminant gut bacteria synthesize odd-chain fatty acids de novo, which then accumulate in animal fat and milk fat. There is also an endogenous route by which mammals can produce small amounts of C17:0, through alpha-oxidation of longer-chain fatty acids and through propionyl-CoA metabolism from branched-chain amino acids, though endogenous synthesis is generally modest relative to dietary intake [1].
C15 and C17:0 as Dietary Biomarkers: What They Reflect and What They Do Not
One of the most established uses of C15 and C17:0 in research is as biomarkers for dairy fat consumption. Because human endogenous synthesis of these acids is limited relative to dietary supply, circulating levels track dairy intake only weakly to moderately (pooled correlations 0.33 with dairy fat and 0.20 with total dairy) [14][15]. Dried blood spot measurements of C15 show good within-person reproducibility over time, and both fatty acids show some sensitivity to changes in high-fat dairy intake, although C17:0 is less reproducible, making them useful tools in nutritional epidemiology [4].
Research note: A pooled analysis of prospective cohorts found higher circulating pentadecanoic acid linked to lower type 2 diabetes risk (HR 0.80 across the 10th to 90th percentile range), and heptadecanoic acid to 0.65. These are observational links with dairy-fat biomarkers [24].
That correspondence is not perfectly clean, however. In rats, circulating C15 fell as total dietary fat content rose even with identical fatty acid composition, while C17:0 did not change significantly, which suggests that [3] the overall fat content of a diet can shift C15 levels even when dairy consumption stays constant [3]. It is also worth noting that C15 and C17:0 are not considered robust biomarkers for dietary fiber intake; fiber evidence is mixed: inulin raised plasma C15 by about 17% in one small crossover trial, while two small human studies found no rise[5][16].
Metabolic Differences: How C15 and C17:0 Are Processed
Despite sharing their odd-chain classification, C15 and C17:0 diverge at the metabolic level. C15 undergoes standard beta-oxidation, eventually yielding propionyl-CoA as its terminal product. C17:0 follows the same pathway but its slightly longer chain and greater potential for endogenous synthesis from propionate metabolism give it a more complex metabolic background [1].
Both acids can be incorporated into cell membranes and lipoproteins. Epitracker researchers have proposed that C15 in particular integrates into cell membranes in ways that may influence membrane stability, and have described it as a partial agonist of PPAR-alpha and PPAR-delta receptors: nuclear receptors involved in fatty acid oxidation and inflammatory signaling. This hypothesis has not yet been independently replicated at scale or formally adopted by regulatory bodies, and it applies specifically to C15. C17:0’s membrane and receptor activities are substantially less characterized in the primary literature.
Fiber evidence is split. In a small crossover trial inulin raised plasma C15 by about 17% and C17:0 by about 11%, yet in 869 Dutch heart attack survivors C15 tracked dairy but not fiber, while C17:0 tracked both [16][25].
A cross-sectional study examining erythrocyte membrane fatty acid composition found that different saturated fatty acids associate differently with glycemic and lipid metabolic markers, reinforcing the point that chain length matters even within the saturated fat category [6].
Cardiometabolic Associations in Observational Research
Both C15 and C17:0 have been examined in relation to cardiometabolic outcomes, with mostly favorable associations in observational data, though some findings point the other way [13][8][17]a pattern that contrasts with older assumptions that all saturated fats carry equivalent cardiovascular risk [7].
Both odd-chain fats track lower diabetes risk, and C17:0 tracks it more strongly
If odd-chain fats matter for diabetes, the stronger signal belongs to C17:0, which is not what C15 supplements contain.
Observational associations in people's blood, not trials: they cannot show that raising either fat prevents diabetes. Contrasts differ between studies, as labelled. Source: Forouhi et al., The Lancet Diabetes & Endocrinology 2014; Imamura et al., PLoS Medicine 2018; Sun et al., European Journal of Preventive Cardiology 2025.
Data table
| Comparison | Estimate | 95% CI |
|---|---|---|
| EPIC-InterAct, Europe (per SD) | 0.79 | 0.73 to 0.85 |
| EPIC-InterAct, Europe (per SD) | 0.67 | 0.63 to 0.71 |
| 16 cohorts, 63,682 adults (10th vs 90th pct) | 0.80 | 0.73 to 0.87 |
| 16 cohorts, 63,682 adults (10th vs 90th pct) | 0.65 | 0.59 to 0.72 |
| Meta-analysis, 112,193 people (10th vs 90th pct) | 0.74 | 0.68 to 0.80 |
| Meta-analysis, 112,193 people (10th vs 90th pct) | 0.65 | 0.61 to 0.71 |
Chart: c15hub.com: Both odd-chain fats track lower diabetes risk, and C17:0 tracks it more strongly
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
A 2025 cross-sectional analysis of NHANES data found that higher serum levels of both C15 and C17:0 were associated with lower odds of hypertension, with associations remaining significant after adjustment for common confounders [2]. Cross-sectional data cannot establish causation, and it is plausible that the overall dietary context of dairy consumption, rather than C15 or C17:0 specifically, drives some of these signals.
The same survey found the link weakened at higher C15: above 1.5 per mille of total fatty acids there was no significant association with hypertension. Mendelian randomization found no evidence that C15 causally affects blood pressure or hypertension [2][17].
In the EPIC-Potsdam cohort, a targeted lipidomic analysis found that odd-chain fatty acid content in specific lipid fractions was associated with reduced type 2 diabetes risk in women, but not in men, where lysophosphatidylcholine(C15:0) was linked to higher risk (HR 1.96)[8]. As with the hypertension data, these associations are observational and may partly reflect broader dietary patterns rather than a direct effect attributable to either fatty acid in isolation.
Immune and Inflammatory Associations
Emerging research has begun to examine odd-chain fatty acid status in relation to immune function. A 2025 prospective cohort study in individuals with psoriasis found associations between plasma levels of odd-chain fatty acids and specific immune cell traits, suggesting these fatty acids may interact with immune regulation differently from even-chain saturated fats [9]. The underlying mechanisms are not yet established, and findings in a psoriasis population may not generalize.
The literature on C17:0 and immune outcomes is considerably less developed than for C15. Because C15 has attracted dedicated supplementation interest and mechanistic research funding, particularly from the Epitracker group, the published cellular and immune literature skews heavily toward C15. C17:0 remains primarily characterized through population-level observational studies rather than controlled interventions.
Key Distinctions Between C15 and C17:0: A Practical Summary
Several meaningful distinctions emerge from the evidence. First, C15 looks less affected by the body’s own synthesis than C17:0 in mice (C17:0 but not C15 fell in Hacl1 knockouts), but human fiber and propionate studies show C15 can rise through endogenous routes too, so neither is a pure dairy marker[1][18][16][19]. Second, the hypothesis that C15 may be ‘conditionally essential’, meaning the body cannot reliably produce it in sufficient quantity, has been advanced by Epitracker researchers, though this classification has not been adopted by mainstream regulatory or nutritional science bodies. No comparable hypothesis exists for C17:0.
Third, human supplementation research involves C15 only: one small 12-week trial at 200 mg/day reported no significant adverse events. C17:0 has been tested only in animals, where supplementation in high-fat-fed mice did not improve liver fat [20][21]. There is currently no supplement-based research on C17:0 to compare against. Fourth, both fatty acids show similar epidemiological patterns, neutral-to-favorable cardiometabolic signals in observational data, but neither has been evaluated by the FDA for any disease treatment or prevention indication.
A broader note: the odd-chain fatty acid family continues to expand in research interest. Investigations into related acids such as nonadecanoic acid (C19:0) are identifying novel metabolic roles, including in glucose homeostasis [10], suggesting these lesser-studied fats as a group may deserve more scientific attention than they have historically received.
🛒 Where to Buy Pentadecanoic Acid (C15)
- Fatty15 (official site) 20% off with code SFKKDBQQ
capsules, 100 mg C15 per capsule; 1 capsule/day starter, 2 capsules/day maintenance: Category creator, from the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15
capsules, 200 mg C15 per serving (2 capsules): Generic C15 supplement; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15
softgels, 100 mg C15 per softgel: Established supplement brand with strong Amazon presence; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15)
powder, 100 to 300 mg per measured serving: Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. C15 products vary widely in how much pentadecanoic acid they actually contain, so check that the Supplement Facts panel lists C15 in milligrams as its own line item rather than bundling it into a fatty acid blend, and compare the per-serving dose with the 200 mg a day used in the one small published human trial [20].
A Note on the Evidence
The health associations reported for C15 and C17:0 are drawn from observational studies, which cannot establish causation; confounding from overall diet quality and dairy consumption patterns is a significant limitation throughout this literature. Individuals who are pregnant, managing cardiovascular or metabolic conditions, or taking lipid-affecting medications should consult a qualified healthcare provider before modifying their dietary fat intake or adding any fatty acid supplement.
Frequently Asked Questions
What is margaric acid?
Margaric acid is the common name for heptadecanoic acid, a 17-carbon saturated odd-chain fatty acid (C17:0). It occurs naturally in full-fat dairy products and ruminant meat, and can be produced in small amounts endogenously via propionate and branched-chain amino acid metabolism [1]. Despite sharing a name root with ‘margarine,’ it is a naturally occurring fatty acid, not a processing artifact.
Are C15 and C17:0 reliable biomarkers for dairy fat intake?
C15 is a moderately useful proxy for dairy fat consumption in population research and was fairly stable within a person over six months (ICC 0.62), while C17:0 was much less stable (ICC 0.32)[4][15]. However, total dietary fat content, not just dairy, influences circulating C15 levels, although C17:0 levels did not change significantly in that study, so C15 in particular does not perfectly isolate dairy-specific consumption [3].
Do C15 and C17:0 work the same way in the body?
They share key metabolic features, both are odd-chain saturated fatty acids yielding propionyl-CoA upon beta-oxidation, but differ in their endogenous synthesis potential and the depth to which each has been mechanistically studied. C15 has been the focus of more supplementation and cellular-mechanism research, while C17:0 is primarily characterized in epidemiological data [1].
What does the research say about these fatty acids and type 2 diabetes?
Observational data from the EPIC-Potsdam cohort found that higher odd-chain fatty acid content in certain lipid fractions was associated with reduced type 2 diabetes risk in some groups, but not in men, and free C17:0 was linked to higher risk in women[8]. These are associations in one specific cohort and cannot be interpreted as evidence that increasing C15 or C17:0 intake prevents diabetes.
Can you supplement with C17:0 the way you can with C15?
Commercially available supplements focus on C15; the one published human trial used 200 mg/day for 12 weeks and reported no significant adverse events [20]. There are no dedicated C17:0 supplements in the published research literature and no comparable intervention trials exist for C17:0.
Are these saturated fatty acids safe to consume?
Observational evidence on C15 and C17:0 is mostly favorable for type 2 diabetes but not uniformly: higher serum C15 was linked to higher islet autoimmunity risk in high-risk infants (OR 3.41), to lower lean mass in several studies, and to higher type 2 diabetes risk for one lipid fraction in men[2][8][13][22][23]. The broader conversation on saturated fat acknowledges that different saturated fatty acids carry meaningfully different metabolic profiles and should not be treated as a uniform group [7]. Individuals with specific health conditions should discuss dietary fat changes with a healthcare provider before making modifications.
References
- Jenkins B et al. A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease. Molecules (Basel, Switzerland) (2015). PMID 25647578
- Chen T et al. Associations between serum pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) levels and hypertension: a cross-sectional analysis of NHANES data. Lipids in health and disease (2025). PMID 40542410
- Jenkins B et al. The Dietary Total-Fat Content Affects the In Vivo Circulating C15:0 and C17:0 Fatty Acid Levels Independently. Nutrients (2018). PMID 30400275
- Albani V et al. Within-person reproducibility and sensitivity to dietary change of C15:0 and C17:0 levels in dried blood spots: Data from the European Food4Me Study. Molecular nutrition & food research (2017). PMID 28544702
- Wu Y et al. Odd Chain Fatty Acids Are Not Robust Biomarkers for Dietary Intake of Fiber. Molecular nutrition & food research (2021). PMID 34605164
- Wu S et al. Differential Associations of Erythrocyte Membrane Saturated Fatty Acids with Glycemic and Lipid Metabolic Markers in a Chinese Population: A Cross-Sectional Study. Nutrients (2024). PMID 38794744
- Dawczynski C et al. Saturated fatty acids are not off the hook. Nutrition, metabolism, and cardiovascular diseases : NMCD (2015). PMID 26626084
- Prada M et al. Association of the odd-chain fatty acid content in lipid groups with type 2 diabetes risk: A targeted analysis of lipidomics data in the EPIC-Potsdam cohort. Clinical nutrition (Edinburgh, Scotland) (2021). PMID 34364238
- Shi R et al. Association between plasma odd-chain fatty acid levels and immune cell traits in psoriasis: insights from a prospective cohort study. Frontiers in immunology (2025). PMID 40356914
- Hou Y et al. A Novel Function of Nonadecanoic Acid in Regulating Glucose Homeostasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID 41738141
- Vissers LET et al. Consumption of a diet high in dairy leads to higher 15:0 in cholesteryl esters of healthy people when compared to diets high in meat and grain. Nutrition, metabolism, and cardiovascular diseases : NMCD (2020). PMID 32139254
- Brevik A et al. Evaluation of the odd fatty acids 15:0 and 17:0 in serum and adipose tissue as markers of intake of milk and dairy fat. European journal of clinical nutrition (2005). PMID 16118654
- Hakola L et al. Serum fatty acids and risk of developing islet autoimmunity: A nested case-control study within the TRIGR birth cohort. Pediatric diabetes (2021). PMID 33543815
- Ilse G. Pranger et al. Fatty acids as biomarkers of total dairy and dairy fat intakes: a systematic review and meta-analysis. Nutrition Reviews (2018). PMID 30307550
- Viviana Albani et al. Exploring the association of dairy product intake with the fatty acids C15:0 and C17:0 measured from dried blood spots in a multipopulation cohort: Findings from the Food4Me study. Molecular Nutrition & Food Research (2015). PMID 26678873
- Weitkunat K et al. Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway for endogenous production from propionate. The American journal of clinical nutrition (2017). PMID 28424190
- Brian T. Steffen et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in Nutrition (2026). PMID 41743064
- Benjamin Jenkins et al. Peroxisomal 2-Hydroxyacyl-CoA Lyase Is Involved in Endogenous Biosynthesis of Heptadecanoic Acid. Molecules (2017). PMID 29027957
- Pfeuffer M et al. Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids. Advances in nutrition (Bethesda, Md.) (2016). PMID 27422507
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- Bishop CA et al. Heptadecanoic Acid Is Not a Key Mediator in the Prevention of Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. Nutrients (2023). PMID 37432205
- Peng W et al. The causal relationship of human blood metabolites with the components of Sarcopenia: a two-sample Mendelian randomization analysis. BMC geriatrics (2024). PMID 38622574
- Santos HO et al. Plasma saturated fatty acids are inversely associated with lean mass and strength in adults: NHANES 2011-2012. Prostaglandins, leukotrienes, and essential fatty acids (2025). PMID 39938186
- Imamura F et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS medicine (2018). PMID 30303968
- Kamalita Pertiwi et al. Associations of dairy and fiber intake with circulating odd-chain fatty acids in post-myocardial infarction patients. Nutrition & Metabolism (2019). PMID 31754368
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.